Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact on Impulse Control Disorders
Objective: Evaluate effect of apomorphine sublingual film (APL-130277; APL) on impulse control disorders (ICD) in patients with Parkinson’s disease (PD) and “OFF” episodes. Background: In…Long term safety of levodopa/carbidopa infusion with ND0612: Results from a phase 2b, international, open-label study
Objective: The primary objective of this long-term study was to evaluate the safety and tolerability of a 24-hour regimen and a 16-hour ‘waking day’ regimen…Interpretation of health-related quality of life outcomes from the EARLYSTIM Study
Objective: To conduct a secondary analysis of the EARLYSTIM study1 to 1: Quantify the meaning of HRQoL outcomes and 2: Evaluate the changes of disease…Real Time Quality Control for Subjective Endpoints in Clinical Trials
Objective: Here we present a system which is capable of performing nearly-real time monitoring of UPDRS part-3 motor assessments using a combination of multidimensional statistics…Dose Optimization of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients with Parkinson’s Disease: Clinical and Exposure Response Findings
Objective: Evaluate if dose optimization (DO) of apomorphine sublingual film (APL-130277; APL) can achieve improved FULL “ON” response in patients with Parkinson’s disease (PD) and…Postmenopausal hormone therapy and Alzheimer’s disease, dementia, and Parkinson’s disease: A systematic review and time-response meta-analysis
Objective: The study aim was to determine the relation between menopausal hormone therapy and Alzheimer's disease, dementia, and Parkinson's disease in human subjects. Background: We…Combined therapy VS only levodopa therapy in a 5-years follow up cohort
Objective: Describe the frequencies of appearance of motor fluctuations, impulse control disorders, in two therapeutic regimes: combined therapy (levodopa plus an other antiparkinsonian drug) or…Efficacy of opicapone compared to entacapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations: A post-hoc conservative analysis
Objective: To assess the efficacy of opicapone 50 mg (OPC 50 mg), compared with entacapone (ENT), in catechol-O-methyltransferase inhibitor (COMTi)-naïve Parkinson’s disease (PD) patients recently…Calcitriol Treatment Attenuates Dopaminergic Neurodegeneration in Mice Model of Parkinson’s Disease
Objective: To investigate the role and mechanism of Calcitriol (1,25-dihydroxyvitamin D3) in Parkinson's mice and cell model Background: Parkinson's disease (PD) is a neurodegenerative disorder…Effect of opicapone and entacapone on levodopa short duration response
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on levodopa short duration response (SDR). Background: OPC, a once-daily catechol-O-methyltransferase inhibitor,…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 149
- Next Page »